Literature DB >> 22736093

How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?

Anne M Kerola1, Markku J Kauppi, Tuomas Kerola, Tuomo V M Nieminen.   

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease which is associated with an increased cardiovascular (CV) burden. Whether the risk is already present at the time of RA diagnosis remains a key area of debate. The aim of this review was to evaluate the existence of both subclinical CV changes, including endothelial dysfunction and atherosclerosis, CV risk factors, as well as CV disease manifestations such as coronary heart disease, myocardial infarction, congestive heart failure and CV death prior to RA diagnosis and during the first few years of the disease. The state of the endothelial function remains controversial in patients with newly diagnosed RA. Studies with impaired brachial artery vasodilatory responses at baseline showed a reversal of the dysfunction after 6-12 months of anti-inflammatory therapy. Morphological evidence of arterial wall atherosclerosis, measured by carotid artery intima-media thickness or the prevalence of carotid plaques, was already present during the first year following RA diagnosis. The risk of coronary heart disease and myocardial infarction is increased even prior to and, at the latest, within 1 year of the clinical onset of RA. The prevalence of hypertension was similar among patients with RA and controls. CV mortality may not increase within the first years of RA diagnosis. In conclusion, the CV risk seems to increase sooner after the RA diagnosis than previously thought. In addition to systematic CV risk assessment, patients with early RA might benefit from being targeted with stricter than conventional CV risk prevention and intervention.

Entities:  

Mesh:

Year:  2012        PMID: 22736093     DOI: 10.1136/annrheumdis-2012-201334

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  25 in total

1.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

Review 2.  Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure.

Authors:  Kerry Wright; Cynthia S Crowson; Sherine E Gabriel
Journal:  Heart Fail Clin       Date:  2014-01-10       Impact factor: 3.179

Review 3.  Cardiovascular effects of approved drugs for rheumatoid arthritis.

Authors:  Fabiola Atzeni; Javier Rodríguez-Carrio; Călin D Popa; Michael T Nurmohamed; Gabriella Szűcs; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2021-04-08       Impact factor: 20.543

4.  Hand osteoarthritis in relation to mortality and incidence of cardiovascular disease: data from the Framingham heart study.

Authors:  Ida K Haugen; Vasan S Ramachandran; Devyani Misra; Tuhina Neogi; Jingbo Niu; Tianzhong Yang; Yuqing Zhang; David T Felson
Journal:  Ann Rheum Dis       Date:  2013-09-18       Impact factor: 19.103

5.  Common atherosclerosis genetic risk factors and subclinical atherosclerosis in rheumatoid arthritis: the relevance of disease duration.

Authors:  Bartłomiej Kisiel; Robert Kruszewski; Aleksandra Juszkiewicz; Anna Raczkiewicz; Artur Bachta; Krzysztof Kłos; Krzysztof Duda; Artur Maliborski; Konrad Szymański; Rafał Płoski; Marek Saracyn; Stanisław Niemczyk; Katarzyna Kisiel; Małgorzata Tłustochowicz; Witold Tłustochowicz
Journal:  Rheumatol Int       Date:  2018-10-29       Impact factor: 2.631

6.  Time-Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk.

Authors:  Kazuki Yoshida; Leslie R Harrold; Nicole Middaugh; Hongshu Guan; Scott Stryker; Elaine Karis; Daniel H Solomon
Journal:  ACR Open Rheumatol       Date:  2022-04-10

Review 7.  Targeting interleukin-6 in rheumatoid arthritis.

Authors:  Md Yuzaiful Md Yusof; Paul Emery
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

8.  The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis.

Authors:  Ruth Davies; Jessica Williams; Katie Sime; Hyun-Sun Jin; Charlotte Thompson; Lauren Jordan; Derek Lang; Julian P Halcox; Elizabeth Ellins; Gareth W Jones; Simon A Jones; Stefan Rose-John; Anwen Williams; Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2021-06-18       Impact factor: 7.580

9.  Cardiovascular Risk and Endothelial Dysfunction in Primary Sjogren Syndrome Is Related to the Disease Activity.

Authors:  Anna Łuczak; Rafał Małecki; Michał Kulus; Marta Madej; Ewa Szahidewicz-Krupska; Adrian Doroszko
Journal:  Nutrients       Date:  2021-06-17       Impact factor: 5.717

Review 10.  Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies.

Authors:  Mir Sohail Fazeli; Vadim Khaychuk; Keith Wittstock; Boris Breznen; Grace Crocket; Mir-Masoud Pourrahmat; Leticia Ferri
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.